Clinical Trials Logo

Clinical Trial Summary

IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure. The disease can affect almost any anatomic location, but the sites involved most commonly are the pancreas, salivary glands, orbital adnexa, lymph nodes, and retroperitoneum. IgG4-RD, typically diagnosed among individuals who are middle-aged, is characterized by a male predominance except with regard to organs of the head and neck (e.g., the salivary glands and orbits), where the gender distribution is approximately equal. The epidemiology of IgG4-RD remains poorly understood because of its recognition only recently as a multi-organ disease. However, IgG4-RD accounts for many conditions once regarded as disparate, single-organ disorders The purpose of our study is to evaluate the method of plasmablast measurement in peripheral blood of IgG4-RD patients, for diagnosis and follow-up on disease progression and response to treatment. This document will outline the collection, processing and testing procedures for measuring plasmablasts from IgG4-RD patients


Clinical Trial Description

IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure. The disease can affect almost any anatomic location, but the sites involved most commonly are the pancreas, salivary glands, orbital adnexa, lymph nodes, and retroperitoneum. IgG4-RD, typically diagnosed among individuals who are middle-aged, is characterized by a male predominance except with regard to organs of the head and neck (e.g., the salivary glands and orbits), where the gender distribution is approximately equal. The epidemiology of IgG4-RD remains poorly understood because of its recognition only recently as a multi-organ disease. However, IgG4-RD accounts for many conditions once regarded as disparate, single-organ disorders.

The current gold standard for the diagnosis of IgG4-RD is the identification of characteristic histology and immunohistochemistry features through biopsy. These pathology features are consistent across the full range of organs affected by IgG4-RD. However, histopathologic variation can occur according to the stage of the lesion; that is, longstanding disease may be predominately fibrotic and a cellular. Confirming the diagnosis of IgG4-RD in such cases can be difficult. Moreover, IgG4-RD organ pathology and IgG4-RD mimickers, such as granulomatosis with polyangiitis (formerly Wegener's), sarcoidosis, histiocytosis, and malignancies (e.g., lymphoma and adenocarcinoma of the pancreas), may share similar features including an IgG4-positive plasma cell infiltrate. Reliance upon serum IgG4 concentrations to diagnose IgG4-RD is similarly problematic because both the specificity and positive predictive value of serum IgG4 concentrations are poor.

Plasmablasts, derived from the B-cell lineage and characterized as CD19lowCD20−CD38+CD27+, comprise a stage intermediate between activated B-cells and plasma cells. Plasmablasts are generally rare in the peripheral blood of healthy individuals, but expansions are observed briefly during responses to infection or vaccination. In contrast, in the setting of autoimmunity and persistent self-antigen(s), plasmablasts can circulate for prolonged periods.

Circulating plasmablasts have been described previously in inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and multiple myeloma. Recently, several studies identified plasmablsts in IgG4-RD both as a diagnostic tool and as an indicator of response to treatment

2. Aim

The purpose of our study is to evaluate the method of plasmablast measurement in peripheral blood of IgG4-RD patients, for diagnosis and follow-up on disease progression and response to treatment. This document will outline the collection, processing and testing procedures for measuring plasmablasts from IgG4-RD patients.

3. Plasmablast source

Plasmablasts will be isolated from peripheral blood derived from patients and normal donors who consent to participate in the study. Blood samples will be drawn by a physician or accredited nurse, transferred to the research lab in order to separate PMBCs, which will be stained for CD19lowCD20−CD38+CD27+ markers and measured by flow cytometry (FACS) located at the hematology lab ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03466970
Study type Observational
Source Meir Medical Center
Contact yael Eizikovits, Mrs
Phone 972-09-7471936
Email yael.eizikovits@clalit.org.il
Status Not yet recruiting
Phase N/A
Start date April 1, 2018
Completion date April 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03368274 - To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom Phase 4
Not yet recruiting NCT03267875 - A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood N/A
Completed NCT02616705 - Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
Completed NCT03669861 - Safety and Efficacy of Abatacept in IgG4-Related Disease Phase 2
Recruiting NCT05625581 - Tofatib Treatment for IgG4-related Disease
Recruiting NCT04125511 - Characterizing IgG4-RD With 68Ga-FAPI PET/CT Early Phase 1
Not yet recruiting NCT06285539 - Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Phase 2
Not yet recruiting NCT05746689 - Study of Sirolimus in IgG4-related Disease N/A
Completed NCT03690908 - Infraorbital Nerve Involvement on Magnetic Resonance Imaging in IgG4-related Ophthalmic Disease
Completed NCT02899039 - Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease N/A
Recruiting NCT04660565 - Belimumab Treatment for IgG4-related Disease Phase 4
Recruiting NCT01670695 - A Prospective Cohort Study of IgG4RD in China N/A
Recruiting NCT03023371 - National Registry of IgG4-RD in China N/A
Unknown status NCT01758393 - Glucocorticoids in Patients With IgG4-RD Phase 2/Phase 3
Completed NCT02705638 - Treatment of IgG4-Related Disease With Revlimid and Rituximab Phase 1
Recruiting NCT03473912 - Meir Medical Center Rheumatologic Biobank